Cargando…
Current state of Alzheimer’s fluid biomarkers
Alzheimer’s disease (AD) is a progressive neurodegenerative disease with a complex and heterogeneous pathophysiology. The number of people living with AD is predicted to increase; however, there are no disease-modifying therapies currently available and none have been successful in late-stage clinic...
Autores principales: | Molinuevo, José Luis, Ayton, Scott, Batrla, Richard, Bednar, Martin M., Bittner, Tobias, Cummings, Jeffrey, Fagan, Anne M., Hampel, Harald, Mielke, Michelle M., Mikulskis, Alvydas, O’Bryant, Sid, Scheltens, Philip, Sevigny, Jeffrey, Shaw, Leslie M., Soares, Holly D., Tong, Gary, Trojanowski, John Q., Zetterberg, Henrik, Blennow, Kaj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280827/ https://www.ncbi.nlm.nih.gov/pubmed/30488277 http://dx.doi.org/10.1007/s00401-018-1932-x |
Ejemplares similares
-
CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
por: Hansson, Oskar, et al.
Publicado: (2018) -
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
por: Ferrero, James, et al.
Publicado: (2016) -
CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004) -
Introduction to special issue on Advances in blood-based biomarkers of Alzheimer's disease
por: O'Bryant, Sid E.
Publicado: (2016) -
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
por: Tran, Jonathan Q, et al.
Publicado: (2016)